Johnson & Johnson (NYSE: JNJ) has recently announced encouraging outcomes from the second interim analysis of the Phase 3 CARTITUDE-4 study, which is pivotal in the evolving landscape of multiple myeloma treatment. This significant study assesses the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) against the standard therapies, which include combinations of pomalidomide, bortezomib, and dexamethasone […]
In a significant development in the healthcare industry, Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) have announced a favorable vote by the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) regarding Abecma (idecabtagene vicleucel). The committee’s 8-3 vote supports the therapy’s benefit/risk profile for patients with triple-class exposed […]
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Orphan Drug Designation to its cutting-edge treatment for multiple myeloma, P-BCMA-ALLO1. This novel therapy, a B-cell maturation antigen (BCMA)-targeted allogeneic T stem cell memory (TSCM)-rich […]
